Najmul Hasan Forhad: VWF Concentrates in Modern Hematology and Transfusion Medicine
Najmul Hasan Forhad, Medical Laboratory Technician at Doctors Without Borders, shared on LinkedIn:
”Topic : Immunohematology and Hemostasis
von Willebrand factor (vWF) concentrates is essential in both clinical practice and laboratory medicine, especially when managing patients with von Willebrand disease (vWD) and certain cases of hemophilia A.
Several therapeutic products are commonly used in replacement therapy, including Alphanate, Humate P, Wilate, and recombinant von Willebrand factor preparations.
Alphanate and Humate P are plasma-derived concentrates containing both vWF and factor VIII, providing effective hemostatic support in patients with bleeding disorders.
Humate P is particularly recognized for its predictable vWF:FVIII ratio and is widely used in surgical prophylaxis and severe bleeding management.
Wilate is another plasma-derived product that is highly purified and formulated to closely resemble the physiologic balance between vWF and factor VIII.
It is commonly used for both acute treatment and prophylactic therapy.
Recombinant von Willebrand factor products represent an important advancement in transfusion medicine and hematology.
Because they are not plasma-derived, they minimize the risk of blood-borne pathogen transmission and offer a more targeted therapeutic approach.
From an educational and examination perspective, understanding the differences between plasma-derived and recombinant products, their clinical indications, and their role in different subtypes of vWD remains highly important for laboratory professionals and healthcare practitioners.
Clinical laboratory science continues to play a critical role in bridging diagnostic hematology with evidence-based patient management.”
Stay updated with Hemostasis Today.
-
May 19, 2026, 16:10Anirban Sen Gupta: Lyophilized Synthetic Platelets as a Stable Powder for Rapid Hemorrhage Control
-
May 19, 2026, 16:02Stroke Foundation Contributes to National Roundtable on Women’s Cardiovascular Health
-
May 19, 2026, 15:57Explore the Emerging Science Behind Factor XI/XIa Inhibition on the ISTH Academy – ISTH
-
May 19, 2026, 15:55Highlighting Key Achievements and Critical Updates from Iran’s National Blood System – IBTO
-
May 19, 2026, 15:54Joanna Fraser: New Publications on Women and Girls With Inherited Bleeding Disorders
-
May 19, 2026, 15:53Nicolas Hubacz: What You Should Know about Hantavirus
-
May 19, 2026, 15:53John Kowal: AHA/ASA Guidelines for Early Stroke Care Now Include Mobile Stroke Units
-
May 19, 2026, 15:52Cedric Hermans: Proposing a New 3-tier Framework for FVIII Replacement Therapy in Hemophilia A
-
May 19, 2026, 15:51Daniel soffer: ApoA-1 vs HDL-C as Markers of Cardiovascular Risk